JP2014506150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506150A5 JP2014506150A5 JP2013543931A JP2013543931A JP2014506150A5 JP 2014506150 A5 JP2014506150 A5 JP 2014506150A5 JP 2013543931 A JP2013543931 A JP 2013543931A JP 2013543931 A JP2013543931 A JP 2013543931A JP 2014506150 A5 JP2014506150 A5 JP 2014506150A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- patients
- data
- population
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012360 testing method Methods 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 63
- 208000024827 Alzheimer disease Diseases 0.000 claims description 61
- 238000003066 decision tree Methods 0.000 claims description 37
- 208000010877 cognitive disease Diseases 0.000 claims description 35
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 26
- 239000000090 biomarker Substances 0.000 claims description 22
- 238000012549 training Methods 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 230000003557 neuropsychological effect Effects 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000012879 PET imaging Methods 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 238000002059 diagnostic imaging Methods 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 238000010855 neuropsychological testing Methods 0.000 description 43
- 238000003745 diagnosis Methods 0.000 description 18
- 238000005259 measurement Methods 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 8
- 238000002790 cross-validation Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000013102 re-test Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000019771 cognition Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000021476 total parenteral nutrition Nutrition 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 241000224511 Bodo Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011328 necessary treatment Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012034 trail making test Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424829P | 2010-12-20 | 2010-12-20 | |
| US61/424,829 | 2010-12-20 | ||
| PCT/IB2011/055584 WO2012085743A2 (en) | 2010-12-20 | 2011-12-09 | Methods and systems for identifying patients with mild cognitive impairment at risk of converting to alzheimer's |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506150A JP2014506150A (ja) | 2014-03-13 |
| JP2014506150A5 true JP2014506150A5 (https=) | 2015-08-20 |
| JP6034800B2 JP6034800B2 (ja) | 2016-11-30 |
Family
ID=45478401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543931A Active JP6034800B2 (ja) | 2010-12-20 | 2011-12-09 | アルツハイマー病へ進行するリスクのある軽度認知障害患者を識別する方法およびシステム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9367817B2 (https=) |
| EP (1) | EP2656257A2 (https=) |
| JP (1) | JP6034800B2 (https=) |
| CN (1) | CN103392183B (https=) |
| RU (1) | RU2603601C2 (https=) |
| WO (1) | WO2012085743A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9152918B1 (en) * | 2012-01-10 | 2015-10-06 | Cerner Innovation, Inc. | Resource forecasting using Bayesian model reduction |
| US9275334B2 (en) * | 2012-04-06 | 2016-03-01 | Applied Materials, Inc. | Increasing signal to noise ratio for creation of generalized and robust prediction models |
| WO2015018517A1 (en) * | 2013-08-05 | 2015-02-12 | Mr. PD Dr. NIKOLAOS KOUTSOULERIS | Adaptive pattern recognition for psychosis risk modelling |
| US20150269355A1 (en) * | 2014-03-19 | 2015-09-24 | Peach Intellihealth, Inc. | Managing allocation of health-related expertise and resources |
| CN105096294B (zh) | 2014-04-30 | 2019-01-18 | 西门子医疗保健诊断公司 | 用于对尿液沉渣图像的待处理区块进行区块检索的方法和装置 |
| CN104031139B (zh) * | 2014-06-06 | 2016-05-04 | 西安交通大学医学院第一附属医院 | 用于阿尔茨海默病pet成像的正电子药物及其制备方法 |
| US11037070B2 (en) * | 2015-04-29 | 2021-06-15 | Siemens Healthcare Gmbh | Diagnostic test planning using machine learning techniques |
| JP6207547B2 (ja) * | 2015-05-18 | 2017-10-04 | 国立大学法人東北大学 | 認知症の程度を判定するための方法、システム及びプログラム |
| EP3451919A4 (en) * | 2016-05-05 | 2019-12-18 | Bestbrain Ltd. | NERVOUS FEEDBACK SYSTEMS AND METHODS |
| JP6515426B2 (ja) * | 2016-09-28 | 2019-05-22 | 公益財団法人神戸医療産業都市推進機構 | 認知症介護負担度判定装置、認知症介護負担度判定方法、認知症介護負担度判定プログラム、認知症治療効果判定装置、認知症治療効果判定方法、及び認知症治療効果判定プログラム |
| JP6845716B2 (ja) * | 2017-03-14 | 2021-03-24 | 一般社団法人脳と心の健康科学研究所 | 生体機能についての医学的検査の得点判定装置、及びプログラム |
| JP6791361B2 (ja) * | 2017-03-30 | 2020-11-25 | 日本電気株式会社 | 情報処理装置と方法とプログラム |
| CN108256422B (zh) * | 2017-12-07 | 2021-11-09 | 广东技术师范大学 | 基于高斯过程分类的阿尔茨海默症分类方法、系统及装置 |
| KR102064811B1 (ko) * | 2018-01-19 | 2020-01-13 | 사회복지법인 삼성생명공익재단 | 아밀로이드 양성 경도인지장애 환자의 치매 진행을 예측하여 분류하는 방법 및 장치 |
| JP6483890B1 (ja) * | 2018-04-27 | 2019-03-13 | 国立大学法人滋賀医科大学 | 診断支援装置、機械学習装置、診断支援方法、機械学習方法および機械学習プログラム |
| US20220073986A1 (en) * | 2018-09-18 | 2022-03-10 | Vivid Genomics, Inc. | Method of characterizing a neurodegenerative pathology |
| CN110944232B (zh) * | 2018-09-21 | 2021-11-19 | 中国移动通信有限公司研究院 | 一种监测认知行为的方法、装置及机顶盒 |
| US12100517B2 (en) | 2018-10-29 | 2024-09-24 | Flatiron Health, Inc. | Generalized biomarker model |
| JP7313165B2 (ja) * | 2019-03-18 | 2023-07-24 | 株式会社Erisa | アルツハイマー病生存分析装置及びアルツハイマー病生存分析プログラム |
| WO2020212843A1 (en) * | 2019-04-15 | 2020-10-22 | Janssen Pharmaceutica Nv | System and method for detecting cognitive decline using speech analysis |
| CN110164524A (zh) * | 2019-04-29 | 2019-08-23 | 北京国润健康医学投资有限公司 | 一种偏瘫患者康复训练任务自适应匹配方法及其系统 |
| WO2021108390A1 (en) * | 2019-11-27 | 2021-06-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | System, method, and computer program product for detecting and responding to patient neuromorbidity |
| JP7334958B2 (ja) * | 2019-12-09 | 2023-08-29 | 学校法人帝京大学 | 判定装置、判定方法及び判定プログラム |
| CN111202526A (zh) * | 2020-01-20 | 2020-05-29 | 华东医院 | 对多维度老年听觉功能评估系统进行精简优化的方法 |
| US11599800B2 (en) * | 2020-01-28 | 2023-03-07 | Color Genomics, Inc. | Systems and methods for enhanced user specific predictions using machine learning techniques |
| US20230042243A1 (en) | 2020-12-09 | 2023-02-09 | MS Technologies | System and method for early diagnostics and prognostics of mild cognitive impairment using hybrid machine learning |
| US11651862B2 (en) | 2020-12-09 | 2023-05-16 | MS Technologies | System and method for diagnostics and prognostics of mild cognitive impairment using deep learning |
| CN117195027A (zh) * | 2023-09-08 | 2023-12-08 | 盐城工学院 | 基于成员选择的簇加权聚类集成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002010456A2 (en) * | 2000-07-31 | 2002-02-07 | The Institute For Systems Biology | Multiparameter analysis for predictive medicine |
| US7347818B2 (en) | 2003-02-24 | 2008-03-25 | Neurotrax Corporation | Standardized medical cognitive assessment tool |
| US7223234B2 (en) * | 2004-07-10 | 2007-05-29 | Monitrix, Inc. | Apparatus for determining association variables |
| US20060099624A1 (en) | 2004-10-18 | 2006-05-11 | Wang Lu-Yong | System and method for providing personalized healthcare for alzheimer's disease |
| WO2006064470A2 (en) * | 2004-12-17 | 2006-06-22 | Koninklijke Philips Electronics, N.V. | Method and apparatus for automatically developing a high performance classifier for producing medically meaningful descriptors in medical diagnosis imaging |
| CN101443780A (zh) * | 2004-12-30 | 2009-05-27 | 普罗文蒂斯公司 | 用于开发和使用用于预测多种医学结果、评价介入策略以及同时验证生物标志物诱因的预测模型的方法、系统和计算机程序产品 |
| WO2006110621A2 (en) | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject |
| JP2008538007A (ja) * | 2005-04-15 | 2008-10-02 | ベクトン，ディッキンソン アンド カンパニー | 敗血症の診断 |
| CN101208602A (zh) * | 2005-04-15 | 2008-06-25 | 贝克顿迪金森公司 | 脓毒症的诊断 |
| WO2006135368A1 (en) | 2005-06-10 | 2006-12-21 | The Trustrees Of Columbia University In The City Of New York | Olfactory identification tests for cognitive diseases and disorders |
| CN101478912A (zh) * | 2006-06-21 | 2009-07-08 | 莱克西克医疗技术有限公司 | 评估痴呆与痴呆型紊乱 |
| US8126690B2 (en) * | 2007-05-18 | 2012-02-28 | The Regents Of The University Of Michigan | Algorithms to predict clinical response, adherence, and shunting with thiopurines |
| CA2737485A1 (en) * | 2008-10-10 | 2010-04-15 | Mount Sinai Hospital | Methods for classifying samples based on network modularity |
| CA2782284A1 (en) * | 2009-11-30 | 2011-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods and systems for isolating, storing, and analyzing vesicles |
-
2011
- 2011-12-09 US US13/995,284 patent/US9367817B2/en active Active
- 2011-12-09 WO PCT/IB2011/055584 patent/WO2012085743A2/en not_active Ceased
- 2011-12-09 EP EP11808350.0A patent/EP2656257A2/en not_active Withdrawn
- 2011-12-09 RU RU2013133904/14A patent/RU2603601C2/ru active
- 2011-12-09 CN CN201180068070.5A patent/CN103392183B/zh not_active Expired - Fee Related
- 2011-12-09 JP JP2013543931A patent/JP6034800B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6034800B2 (ja) | アルツハイマー病へ進行するリスクのある軽度認知障害患者を識別する方法およびシステム | |
| JP2014506150A5 (https=) | ||
| Clarke et al. | Computer-assisted EEG diagnostic review for idiopathic generalized epilepsy | |
| Nasseroleslami et al. | Characteristic increases in EEG connectivity correlate with changes of structural MRI in amyotrophic lateral sclerosis | |
| Bosl et al. | EEG analytics for early detection of autism spectrum disorder: a data-driven approach | |
| US20240188843A1 (en) | Systems and Methods for Generating Biomarkers Based on Multivariate MRI and Multimodality Classifiers for Disorder Diagnosis | |
| CN105793852B (zh) | 具有海量医疗分析的医疗处理计算机规划方法和系统 | |
| Weintraub et al. | Neurodegeneration across stages of cognitive decline in Parkinson disease | |
| McBride et al. | Spectral and complexity analysis of scalp EEG characteristics for mild cognitive impairment and early Alzheimer's disease | |
| Li et al. | LensAge index as a deep learning-based biological age for self-monitoring the risks of age-related diseases and mortality | |
| EP3901963A1 (en) | Method and device for estimating early progression of dementia from human head images | |
| Escudero et al. | Early detection and characterization of Alzheimer's disease in clinical scenarios using Bioprofile concepts and K-means | |
| CN105517488A (zh) | 用于评估、诊断和/或监测心脏健康的装置与方法 | |
| Falach et al. | Annotated interictal discharges in intracranial EEG sleep data and related machine learning detection scheme | |
| Badjatia et al. | Machine learning approaches to prognostication in traumatic brain injury | |
| US20250318767A1 (en) | System and Method for Mental Diagnosis Using EEG | |
| US12569185B2 (en) | Systems and methods for subject assessment | |
| EP4044193A1 (en) | Psychological state monitoring system | |
| Mostile et al. | Testing machine learning algorithms to evaluate fluctuating and cognitive profiles in Parkinson’s disease by motion sensors and EEG data | |
| Miyazaki et al. | Inferring amyloid pathologies among patients with mild cognitive impairment using phase‒amplitude coupling of electroencephalography: A case‒control study | |
| Wang et al. | Local Neuronal Activity and the Hippocampal Functional Network Can Predict the Recovery of Consciousness in Individuals With Acute Disorders of Consciousness Caused by Neurological Injury | |
| Rahmanipour et al. | Artificial intelligence in ophthalmology clinical trials: a narrative review | |
| Liang et al. | Construction of a mild cognitive impairment prediction model for Parkinson’s disease patients on the basis of multimodal data | |
| Althoff et al. | Cognitive-motor interference in multiple sclerosis and healthy controls: results from single, dual, and triple task posturography | |
| Bourque et al. | Discovering Hidden Links: Harnessing Similarity Network Fusion to Reveal Common Clusters in Healthy Aging, Mild Cognitive Impairment, and Dementia |